ArticleJournal of experimental orthopaedics2026
Three injections of freeze-dried platelet factor concentrate provide greater clinical response than single injection in the treatment of knee osteoarthritis.
Article in Journal of experimental orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Single-injection freeze-dried platelet factor concentrate (PFC-FD) has been shown to be safe and effective in the treatment of early knee osteoarthritis (OA) with clear advantages over other PRP processing methods. No previous clinical investigations have examined multiple PFC-FD doses. The aim of this study was to assess the safety and effectiveness of one versus three PFC-FD injections in patients with knee OA. Methods: Patients with Kellgren-Lawrence (KL) Grade I-IV knee OA were prospectively recruited via shared decision-making based on patient preference to receive either one ( Results: The three-injection cohort demonstrated a small advantage in all KOOS subscales except quality of life (QOL) at 1 month (2.4-4.0 points, Conclusion: Based on non-randomized allocation, a three-injection PFC-FD treatment protocol demonstrates a higher likelihood of clinical response compared to a one-injection protocol, particularly for relief of early knee OA symptoms, without evidence of an adverse immune response. Level of Evidence: Level II, prognostic prospective cohort study (patients enroled at different stages of disease progression).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.